These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33369212)

  • 41. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
    Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma.
    Velasco-Rodríguez D; Martínez-Alfonzo I; Velasco-Valdazo AE; Revilla N; Mahíllo-Fernández I; Askari E; Castro-Quismondo N; Laso RV; Domingo-González A; Serrano-López J; Prieto E; Rosado B; Blanchard MJ; Martín-Herrero S; García-Raso A; Bueno MÁ; de la Plaza R; Peñaherrera M; López IG; López-Jiménez J; Martínez-López J; Llamas-Sillero P
    J Thromb Thrombolysis; 2023 Apr; 55(3):464-473. PubMed ID: 36630029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
    Perzborn E; Heitmeier S; Buetehorn U; Laux V
    J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence.
    Gomez-Rosas P; Pesenti M; Verzeroli C; Giaccherini C; Russo L; Sarmiento R; Masci G; Celio L; Minelli M; Gamba S; Tartari CJ; Tondini C; Giuliani F; Petrelli F; D'Alessio A; Gasparini G; Labianca R; Santoro A; De Braud F; Marchetti M; Falanga A;
    TH Open; 2021 Jan; 5(1):e56-e65. PubMed ID: 33585786
    [No Abstract]   [Full Text] [Related]  

  • 48. Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay.
    Carlo A; Yan Q; Ten Cate H; De Laat-Kremers R; De Laat B; Ninivaggi M
    Front Cardiovasc Med; 2022; 9():912433. PubMed ID: 35958413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays.
    Wang J; Lim HY; Nandurkar H; Ho P
    Int J Lab Hematol; 2023 Jun; 45(3):360-367. PubMed ID: 36691357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
    Königsbrügge O; Weigel G; Quehenberger P; Pabinger I; Ay C
    Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
    Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
    Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia
    Efthymiou M; Lane PJ; Isenberg D; Cohen H; Mackie IJ
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
    Molenaar PJ; Dinkelaar J; Leyte A
    Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
    Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
    Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation.
    Bloemen S; Zwaveling S; Mullier F; Douxfils J
    Thromb Res; 2019 Dec; 184():8-15. PubMed ID: 31677449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
    Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
    Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
    Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
    Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.